Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously developed quantitative systems pharmacology model of the anti‐CD20/CD3 T‐cell engaging bispecific antibody, mosunetuzumab, to account for different dosing regimens and patient heterogeneity in the phase I study to inform clinical dose/exposure‐response relationships and to identify biological determinants of clinical response. We developed a novel workflow to generate digital twins for each patient, which together form a virtual population (VPOP) that represented variability in biological, pharmacological, and tumor‐related parameters from the phase I trial. Simulations based on the VPOP predict that an increase in mosunetuzumab exposure increases the proportion of digital twins with at least a 50% reduction in tumor size by day 42. Simulations also predict a left‐shift of the exposure‐response in patients diagnosed with indolent compared to aggressive non‐Hodgkin's lymphoma (NHL) subtype; this increased sensitivity in indolent NHL was attributed to the lower inferred values of tumor proliferation rate and baseline T‐cell infiltration in the corresponding digital twins. Notably, the inferred digital twin parameters from clinical responders and nonresponders show that the potential biological difference that can influence response include tumor parameters (tumor size, proliferation rate, and baseline T‐cell infiltration) and parameters defining the effect of mosunetuzumab on T‐cell activation and B‐cell killing. Finally, the model simulations suggest intratumor expansion of pre‐existing T‐cells, rather than an influx of systemically expanded T‐cells, underlies the antitumor activity of mosunetuzumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Six‐Stage Workflow for Robust Application of Systems Pharmacology
Gadkar, K., Kirouac, D., Mager, D., van der Graaf, P., & Ramanujan, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12071 · Cited by 93
Self-citationJiang, X., Chen, X., Carpenter, T. J., Wang, J., Zhou, R., Davis, H. M., Heald, D. L., & Wang, W. (2018) · mAbs · doi:10.1080/19420862.2018.1480299 · Cited by 60 · cited 1×
“With respect to the relative abundance of target B-cells and T-cells, the B:T-cell ratio has been demonstrated in vitro 19 and in vivo 20 to alter target cell killing by T-cell engaging bispecific antibodies, although it is not currently known whether there are clinical differences in baseline…”
BackgroundLi, C.-C., Bender, B., Yin, S., Li, Z., Zhang, C., Hernandez, G., Kwan, A., Sun, L., Adamkewicz, J. I., Wang, H., et al. (2019) · Blood · doi:10.1182/blood-2019-123961 · Cited by 14
Self-citation
Cited by
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2273839 · Cited by 235
“DTs can be realized in different forms, such as through mechanistic modeling [14,16,27] as well as by using AI [7,15,19,28].”
BackgroundWang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01188-4 · Cited by 122
An industry perspective on current QSP trends in drug development
Cucurull-Sanchez, L. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09905-y · Cited by 37
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · Handbook of Experimental Pharmacology · doi:10.1007/164_2024_735 · Cited by 6
Metadata
- Authors
- Susilo, M. E., Li, C., Gadkar, K., Hernandez, G., Huw, L., Jin, J. Y., Yin, S., Wei, M. C., Ramanujan, S., & Hosseini, I.
- Venue
- Clinical and Translational Science
- Publisher
- Wiley
- Published
- 2023-03-23
- Volume
- 16
- Issue
- 7
- Pages
- 1134-1148
- ISSN
- 1752-8054 (ISSN-L)
- 1752-8062
- OpenAlex
- W4324017666
- Cited by
- 78
- References
- 3
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. https://app.cochat.ai/papers/10.1111/cts.13501
- The paper
- Susilo, M. E., Li, C., Gadkar, K., Hernandez, G., Huw, L., Jin, J. Y., Yin, S., Wei, M. C., Ramanujan, S., & Hosseini, I. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science. https://doi.org/10.1111/cts.13501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.